methylthio-adp has been researched along with mrs 2211 in 1 studies
| Studies (methylthio-adp) | Trials (methylthio-adp) | Recent Studies (post-2010) (methylthio-adp) | Studies (mrs 2211) | Trials (mrs 2211) | Recent Studies (post-2010) (mrs 2211) |
|---|---|---|---|---|---|
| 146 | 2 | 43 | 5 | 0 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, J; Jiang, M; Liao, L; Liu, X; Luo, J; Wang, W; Xiang, F | 1 |
1 other study(ies) available for methylthio-adp and mrs 2211
| Article | Year |
|---|---|
Nucleolin down-regulation is involved in ADP-induced cell cycle arrest in S phase and cell apoptosis in vascular endothelial cells.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Aorta; Apoptosis; Azo Compounds; Cell Line; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Monocytes; Nucleolin; Phosphoproteins; Primary Cell Culture; Proto-Oncogene Proteins c-bcl-2; Purinergic Agonists; Purinergic Antagonists; Pyridoxal Phosphate; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; RNA-Binding Proteins; RNA, Messenger; S Phase Cell Cycle Checkpoints; Signal Transduction; Thionucleotides | 2014 |